Figure 2. Reversion mutation BRCA1 c.617_623del mediates resistance to olaparib and camrelizumab combination therapy (PARPi+ICI). (A) Tabulated summary of the mutations and genomic signatures (such as tumor mutation burden and microsatellite status) detected from blood samples before receiving and after progression from PARPi+ICI. (B) Screenshot of integrated genome viewer showing the sequencing reads for BRCA1 c.617_623delACAAATC detected at progression from PARPi+ICI. (C) Diagram showing the amino acid sequences corresponding to wild-type BRCA1, the germline BRCA1 exon 7-8 deletion, and the BRCA1 c.617_623delACAAATC.

PARPi = poly(ADP-ribose) polymerase inhibitors; ICI = immune checkpoint inhibitors.